Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341727 · ClinicalTrials.gov registry record · Phase 3
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
A Phase 3 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT04341727 is a Phase 3 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 30 participants.
The verdict
NCT04341727, a Phase 3 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.
Interventions
- DRUG Azithromycin
- DRUG Hydroxychloroquine Sulfate
- DRUG Chloroquine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-04-04 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04341727
The ClinicalTrials.gov registry entry for NCT04341727 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.
NCT04341727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04341727 about?
NCT04341727 is a clinical study titled "Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection". This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.
What is the current status of trial NCT04341727?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2020-04-04. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04341727?
The interventions under investigation include: Azithromycin (DRUG), Hydroxychloroquine Sulfate (DRUG), Chloroquine Sulfate (DRUG).
Who is sponsoring clinical trial NCT04341727?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.